Table 1 |.
Demographic, viral data and clinical data of three cohorts
| Total | DVG− | DVG+ | P value | |
|---|---|---|---|---|
| Cohort 1 | ||||
| Number of patients | 122 | 22 | 100 | NA |
| Median age in days (range) | 145.5 (30–714) | 302.5 (42–714) | 116 (30–683) | 0.0052 |
| Sex, M:F | 64:58 | 16:6 | 48:52 | 0.0355 |
| Median viral load Ct value (IQR) | 22.6 (20.6–25.2) | 27.65 (25.7–30.7) | 21.95 (20.3–23.9) | <0.0001 |
| Median length of stay in days (IQR) | 3 (2–5) | 2 (1–3) | 4 (2–5) | 0.0008 |
| Median ICU days (IQR) | 0 (0–2) | 0 (0–0) | 0 (0–2) | NS |
| Cohort 2 (non-hospitalized) | ||||
| Number of patients | 73 | 20 | 53 | NA |
| Median age in weeks (range) | 23.29 (3.29–33) | 23.65 (3.29–33) | 23.14 (5.57–32.43) | NS |
| Sex, M:F | 42:31 | 13:7 | 29:24 | NS |
| Median viral load Ct value (IQR) | 23.91 (20.65–27.29) | 25.61 (23.94–29.78) | 22.82 (20.22–25.80) | 0.0059 |
| Median respiratory severity score (IQR) | 2 (1–4) | 2 (1–4) | 3 (1–4) | NS |
| Sampling days after symptoms (IQR) | 3 (2–4) | 4 (2.25–5.75) | 3 (2–4) | 0.0342 |
| Cohort 2 (hospitalized) | ||||
| Number of patients | 27 | 3 | 24 | NA |
| Median age in weeks (range) | 13.29 (1.57–27.71) | 6.86 (3.71–18.43) | 13.36 (1.57–27.71) | NS |
| Sex, M:F | 14:13 | 1:2 | 13:11 | NS |
| Median viral load Ct value (IQR) | 22.79 (20.44–26.59) | 26.59 (21.59–27.20) | 22.79 (19.94–26.12) | NS |
| Median length of stay in days (IQR) | 3 (1–5) | 2 (1–5) | 3 (1.25–4.75) | NS |
| Sampling days after symptoms (IQR) | 4 (3–5) | 5 (3–5) | 4 (2.25–5) | NS |
| Cohort 3 | ||||
| Number of patients | 56 | 38 | 18 | NA |
| Median age in years (range) | 22 (18–50) | 22 (18–50) | 21 (18–29) | NS |
| Sex, M:F | 35:21 | 28:10 | 7:11 | 0.012 |
| Median total viral load AUC (IQR) | 643.2 (0–34,707) | 503.5 (0–19,737) | 643.2 (1.1–181,479) | NS |
| Median total clinical score (IQR) | 20 (7.3–36.8) | 22 (7.8–43) | 10 (4.8–29.5) | NS |
| Median nasal RSV IgA titer (log2) at baseline (IQR) | 9.61 (8.90–10.41) | 9.93 (8.94–10.42) | 9.43 (8.83–10.46) | NS |
P values are from chi-square test (sex) or two-tailed Mann–Whitney test (the rest) of comparison between cbDVG+ and cbDVG− patients. NA, not applicable; NS, not significant.